Kura Oncology (NASDAQ:KURA) Insider Sells $165,872.50 in Stock

29 Sep 2026, 23:08 by Tristan Rich · The Markets Daily

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) insider Brian Powl sold 15,430 shares of the firm’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total transaction of $165,872.50. Following the completion of the sale, the insider owned 136,819 shares in the company, valued at $1,470,804.25. This represents a 10.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Kura Oncology Price Performance

Shares of KURA traded up $0.20 during trading hours on Tuesday, reaching $10.81. The stock had a trading volume of 1,890,260 shares, compared to its average volume of 1,673,937. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. Kura Oncology, Inc. has a 12 month low of $7.36 and a 12 month high of $13.90. The stock has a market capitalization of $961.66 million, a PE ratio of -3.21 and a beta of 0.44. The company’s 50-day moving average is $11.22 and its two-hundred day moving average is $10.15.

Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The business had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million. Research analysts expect that Kura Oncology, Inc. will post -3.25 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on KURA shares. Wedbush lifted their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a research note on Monday, June 15th. Raymond James Financial set a $24.00 price target on shares of Kura Oncology in a report on Monday, August 24th. CLSA set a $24.00 price target on shares of Kura Oncology in a report on Thursday, June 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and a consensus price target of $25.40.

Read Our Latest Stock Report on Kura Oncology

Institutional Trading of Kura Oncology

Large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its stake in Kura Oncology by 32.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock worth $11,591,000 after purchasing an additional 348,127 shares during the period. Hennion & Walsh Asset Management Inc. lifted its stake in Kura Oncology by 69.7% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock valued at $6,240,000 after buying an additional 233,633 shares during the period. Great Lakes Advisors LLC bought a new position in shares of Kura Oncology during the 2nd quarter worth approximately $2,851,000. Tidal Investments LLC bought a new position in shares of Kura Oncology during the 2nd quarter worth approximately $1,029,000. Finally, Janney Montgomery Scott LLC boosted its holdings in shares of Kura Oncology by 285.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 158,850 shares of the company’s stock worth $1,291,000 after buying an additional 117,650 shares in the last quarter.

More Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

Positive Sentiment: KO-7246 regenerated functional pancreatic beta-cell mass and improved glycemic control in Type 1 and Type 2 diabetes models. Benefits persisted for at least one month after treatment stopped in a Type 1 diabetes model, suggesting potential disease-modifying activity. KO-7246 EASD announcement
Positive Sentiment: The candidate increased beta-cell mass, endogenous insulin and C-peptide levels, and showed enhanced activity when combined with semaglutide. Results in human pancreatic islets also indicated selective beta-cell proliferation and improved glucose-responsive insulin secretion, strengthening the potential commercial value of Kura’s menin-inhibitor platform. KO-7246 preclinical data
Neutral Sentiment: KO-7246 remains preclinical. Caspian plans IND-enabling work and a future Phase 1 study, with management scheduled to discuss the program on October 13. Any valuation benefit for KURA therefore depends on future clinical progress and the terms of Kura’s relationship with Caspian. Caspian and Kura KO-7246 report
Negative Sentiment: Several Kura executives and insiders sold shares on September 28–29, including Mollie Leoni, Brian Powl, Kathleen Ford, Thomas Doyle and Teresa Bair. The transactions totaled approximately 97,000 shares and more than $1 million, signaling near-term insider selling pressure even though the sellers retained substantial holdings. Kura insider ownership filing
Negative Sentiment: The diabetes opportunity carries substantial execution risk, including potential clinical or regulatory setbacks, unexpected safety findings and the need for additional financing before human trials can begin.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.